TABLE 2.
Demographics of the 2 vaccine groups after second dose
| Patient characteristic | Oxford-AstraZeneca | Pfizer-BioNTech (mRNA BNT162b2) | P |
|---|---|---|---|
| Median age, y (range) | 56 (20–87) | 57 (20–87) | 0.5 |
| Latest median BMI (range) | 29.5 (18–40) | 27 (18–35) | 0.2 |
| Median transplant duration, y (range) | 7.75 (3 mo–40 y) | 7.36 (3 mo–33 y) | 0.59 |
| Male/female, n (%) | 208/138 (60.1/39.9) | 150/97 (60.4/39.6) | 0.9 |
| Ethnic group: any White/any Asian/any African background, n (%) | 266/13/3 (76.9/3.8/0.9) | 182/21/1 (73.7/8.5/0.4) | 0.13 |
| Median eGFR (range) | 48.5 (8–110) | 54 (11–120) | 0.09 |
| Diabetes as cause of renal failure, n (%) | 40 (11.5) | 21 (8.5) | 0.22 |
BMI, body mass index; eGFR, estimated glomerular filtration rate.